Palvella Therapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- The FDA accepted Palvella Therapeutics’ New Drug Application for ketorin rapamycin for microcystic lymphatic malformations (MLM), granted priority review, and set a PDUFA target action date of February 28th, 2027.
- Palvella had $236.7 million in cash, cash equivalents, and short-term investments at the end of Q3, compared with approximately $250 million at the end of Q2 2026.
- 3rd-quarter research and development expenses were $10.8 million, compared with $6.5 million in the 3rd quarter of 2025, and G&A expenses were $11.9 million, compared with $3.6 million a year ago.
- Net loss was $24.6 million, or $1.70 per share, compared with a net loss of $11.3 million, or $1.03 per share, in the 3rd quarter of 2025; Q3 2026 net loss included $4.5 million of non-cash charges related to the Ligand royalty agreement.
- The positive Phase 2 TOIVA study in cutaneous venous malformations (CVM) showed that 73% of patients improved on the CVM IgA at week 12; 24-week data presented at PEDRA in October showed additional improvement between week 12 and week 24 on multiple endpoints and reduced disease severity and bleeding in pediatric patients.
- Palvella reported approximately 155,000 diagnosed U.S. DSAP patients in a new claims analysis presented at Fall Clinical Dermatology in October, and more than 90 unsolicited patient requests about the planned trial.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Palvella Therapeutics Third Quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Bohan Wei, Vice President of Corporate Development and New Product Planning. Please go ahead. Thank you, operator.
Good morning, and thank you for joining the Palvella Therapeutics Third Quarter 2026 Financial Results and Corporate Update Call. As a reminder, our press release detailing today's announcements can be found in the Investors section of our website at www.palvellatx.com. On today's call, you will first hear from Wes Kaupinen, our Founder and Chief Executive Officer, followed by Ashley Kline, our Chief Commercial Officer, Dr. Jeff Martini, our Chief Scientific Officer, and Matt Korenberg, our Chief Financial Officer. Before we begin, please note that today's remarks may include forward-looking statements regarding our development program, regulatory strategy, commercial planning, and financial outlook. These statements are based on current assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings for a full discussion of these risk factors. I'll turn the call over to Wes.
Thanks, Bohan. Good morning, everyone, and thank you all for joining us on the Palvella Therapeutics Third Quarter Earnings Call and Corporate Update. For children and adults living with microcystic lymphatic malformations, every day counts. Microcystic lymphatic malformations are a serious, rare, and chronically debilitating genetic disease. Starting at a young age, daily life can be impacted by persistent leaking and bleeding from their lymphatic lesions, functional impairment, infections, disfigurement, and a physical and psychological burden of living with a lifelong infiltrative disease that progressively worsens over time. Despite this profound burden of disease, there are currently no FDA-approved therapies for microcystic lymphatic malformations. Last Wednesday, October 28, a major milestone was achieved that could soon change the treatment paradigm for individuals living with microcystic lymphatic malformations.
Our team at Palvella Therapeutics announced that the FDA has accepted our new drug application for QTORIN rapamycin for the treatment of microcystic LMs, and furthermore, that the program has been granted FDA's Priority Review, a designation for medicines that, if approved, would offer significant improvements in the safety or effectiveness of treating serious conditions, and which sets a six-month FDA review goal rather than the standard 10-month review. In light of this milestone, I want to take a moment to recognize the patients and families who have participated in our clinical studies, our clinical investigators, our patient advocacy collaborators, our highly dedicated employees, and everyone who helped us reach this important point. Thank you. Furthermore, 116 days from today, on February 28, 2027, the Palvella team, working in conjunction with our physician and patient advocacy collaborators, will have the potential opportunity to begin transforming the lives of these patients through the commercialization of QTORIN rapamycin, if approved.
Our goal is not simply to bring another medicine to market. Our goal is to establish QTORIN rapamycin as the first-line treatment and standard of care for microcystic lymphatic malformations. Recently, I was in Fort Lauderdale, Florida, with newly recruited members of our commercial and medical affairs teams. We have recruited an exceptional group of leaders who have helped build and launch some of the most successful products in both rare diseases and dermatology, including individuals like Phil Hazel, Marnie Telkamp, Nick Kerr, Matt Giordano, Erika Luceri-Johnson, and many others.
What struck me was the depth of their experience in launching novel products, their boundless positive energy, and most of all, the shared commitment to delivering on the potential for a highly successful launch for the microcystic lymphatic malformation community. Longer term, an FDA approval in microcystic lymphatic malformations may open the door to many other potential clinical indications where QTORIN rapamycin can make a meaningful impact to patients. The vision for QTORIN rapamycin is a pipeline and a product, one drug that can eventually address many rare skin diseases and vascular anomalies in which the mTOR pathway has been identified to be a key driver of those diseases.
At Palvella, we are striving to realize the full patient impact that QTORIN rapamycin can have, and as you will hear today, we are actively advancing QTORIN rapamycin for multiple additional indications, two of which are in advanced clinical stages in cutaneous venous malformations and clinically significant angiokeratomas, with the goal of delivering multiple first-in-disease therapy to these deserving rare disease patient populations. While we believe QTORIN rapamycin for microcystic lymphatic malformations will represent our first FDA approval and an attractive peak annual U.S. sales opportunity exceeding $1 billion, we believe what truly sets Palvella apart is our ability to repeatedly unlock multi-billion dollar markets in orphan diseases previously thought to be untreatable. The repeatability of our approach is enabled by two elements that are core to Palvella. Number one, our disciplined first-in-disease strategy.
We aim to go from zero to one in serious rare diseases that currently have no FDA-approved therapies. Rather than pursue incremental differentiation in crowded markets, our focus is on pioneering the first approved therapy in diseases where patients have oftentimes been left behind. Number two, our proprietary QTORIN platform, which enables us to reproducibly generate novel IP-protected topical product candidates to address these serious rare skin diseases and vascular malformations. Importantly, at Palvella, we often focus on selecting diseases where there is already human proof-of-concept data supporting the therapeutic approach, frequently from real-world clinical evidence. This provides early but important mechanistic and clinical validation that modulating a specific pathway has the potential to deliver meaningful benefit to patients.
We then apply our QTORIN platform to optimize localized drug targeting, tissue exposure, and tolerability, with the goal of translating that early evidence into compelling clinical outcomes demonstrated in rigorous, well-conducted clinical trials while using endpoints specifically designed to support FDA approvals. Our overarching goal is to bring first-in-disease therapies to FDA approval as quickly and efficiently as possible, recognizing that time matters to rare disease patients, while capital efficiency and the probability of achieving FDA approvals matter to our shareholders, who have entrusted us to translate their investment into high clinical impact, commercially available, FDA-approved therapies. With our NDA now accepted and our PDUFA date set for next sector, I'd like to introduce you to our Chief Commercial Officer, Ashley Kline, who will be leading the launch of QTORIN rapamycin in microcystic lymphatic malformations.
Ashley began working with Palvella more than two years ago, and we formally announced her appointment as Chief Commercial Officer in May of last year. What makes Ashley particularly valuable to Palvella is that she's not preparing for her first successful rare disease launch, she's preparing for her next one, bringing lessons learned from her previous successful launches directly into our preparations for QTORIN rapamycin. While General Manager of Dompé's U.S. business, Ashley led the highly successful launch of OXERVATE, a first-in-disease topical therapy for a rare disease with no previously FDA-approved treatments. Under her leadership, OXERVATE grew to more than $500 million in annual U.S. sales while achieving profitability in its first year. What impresses me most about Ashley is her combination of strategic thinking, relentless execution, and a genuine commitment to patients.
With our potential first approval approaching, I couldn't be more excited about the team that Ashley has recruited, the progress of our launch preparations, thanks to Ashley and her entire team, and our shared determination to deliver for the microcystic LM community. Ashley, over to you. Thanks, Wes.
As Wes mentioned, I've been working with Palvella for a couple of years. Prior to that, I led the launch of OXERVATE, a topical eye drop for the rare eye disease neurotrophic keratitis. Seven years after launch, OXERVATE has grown to more than $1 billion in U.S. sales. I bring that up because the NK market in 2018 looked a lot like what we see today in microcystic lymphatic malformation. Some of the parallels with the launch of QTORIN rapamycin include the lack of an FDA-approved therapy and potential upside from patients who were undiagnosed. I want to spend a few minutes on how we expect this launch to unfold, assuming approval.
While I am proud of what I have achieved previously, what is very exciting about the opportunity at Palvella is the large number of existing diagnosed patients and the organic maturation of vascular anomaly clinics with large numbers of patients receiving specialist care. Some keys for a successful orphan launch are strong prescribing intent, a pathway to coverage with non-clinical barriers addressed and removed, and a patient-finding effort that allows resources and capital to be deployed efficiently. Here is the headline. We expect strong physician demand for QTORIN rapamycin to be there from day one. In our market research with more than 150 physicians, more than 70% said that they would expect to prescribe if approved. On the payer side, we know that payers see value in the product. We have had initial conversations with some plans, and those conversations have been constructive, and I will share more on that in a minute.
Next, a word on the market opportunity and patient identification. We had a lot of confidence in our claims analysis and traditional market research, but at Palvella, we have a culture of refusing to be satisfied, and we continue to invest in refining our view of this market. One recent investment was using a large language model to analyze anonymized chart notes, which unearthed novel treaters and ICD-10 coding patterns, a group that was invisible in traditional claims analysis, indicating potential upside on our internal estimates. We are deploying this novel algorithm now in the largest U.S. database of dermatology encounters, and we look forward to those results. The underlying opportunity is clear. With more than 30,000 diagnosed U.S. patients at $100,000-$200,000 per patient per year, reaching $1 billion at peak requires modest penetration.
Our team is laser-focused on bringing these patients the first FDA-approved therapy for their disease if we receive approval next year. When we received the SELVA data in February, the results of the clinical study exceeded all of our tested scenarios, so we went out to both physicians and payers to do additional market research. The data that I am sharing with you here has not been shared before. This research bolsters our confidence in early uptake. More than 70% of physicians surveyed expect to begin prescribing within three months of approval, and most plan to start several patients at once. Our market access testing confirmed that payers agree MLM is a serious genetic vascular anomaly with unmet need, and they found the SELVA data to provide a compelling clinical evidence package.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
11 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
